Description
Supplementary Protection Certificates (SPCs) remain one of the most importanttools for extending protection on medicinal products. The recent CJEU Grand Chamber judgments in Joined Cases C‑119/22 & C‑149/22 (MSD v Teva / MSD v Clonmel) reshape how SPCs for combination therapies are assessed – with major implications for pharma innovators, IP strategists, and regulatory teams.
Key points to be covered:
• Combination SPCs are still possible;
• The Article 3(a) bar is now set higher;
• The requirement for synergy in combination products;
• Implications for originators and generics companies;
• Practical implications and future perspectives.
The webinar will be presented by Dr Lawrence Cullen, a thought leader in the field of SPCs.
Who Should Attend?
Pharmaceutical IP teams | Regulatory affairs specialists | Patent attorneys | R&D leaders working on combination therapies | Anyone navigating SPC strategy in the EU or UK
Speaker: Dr Lawrence Cullen
Dr Lawrence Cullen is a leading authority on the complex intersection of patent law, regulatory frameworks, and pharmaceutical innovation, with more than 25 years of frontline experience shaping how intellectual property is examined, granted, and defended across biotechnology, chemistry, and pharmaceuticals.
As the former Deputy Director for Biotechnology, Pharmaceuticals & Organic Chemistry at the UK Intellectual Property Office, Dr Cullen spent nearly three decades overseeing teams of specialist scientists, directing patent examination strategy, and issuing final decisions on both patents and Supplementary Protection Certificates (SPCs). His work placed him at the center of some of the most technically demanding and legally significant questions in modern life‑sciences IP – from cutting‑edge biotech inventions to the evolving SPC landscape for human and veterinary medicines.